Status:
UNKNOWN
Sirolimus Combined With Low-dose Warfarin for the Treatment of Refractory PNH
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Paroxysmal Nocturnal Hemoglobinuria
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
Classical paroxysmal nocturnal hemoglobinuria(PNH) is mainly characterized by hemolysis and thrombosis, which reduced patients ' quality of life(QoL) greatly and even lead to death. Glucocorticoids an...
Detailed Description
Classical paroxysmal nocturnal hemoglobinuria(PNH) is mainly characterized by hemolysis and thrombosis, which reduced patients ' quality of life(QoL) greatly and even lead to death. There is no ideal ...
Eligibility Criteria
Inclusion
- age 18-70 years
- diagnosed with PNH and no thrombosis
- ineffective, relapsed or intolerant to conventional treatment (eg glucocorticoids, • • iron, folic acid, androgen, etc.)
- not available for hematopoietic stem cell transplantation
- ECOG≤2
- agreed to sign the consent forms
Exclusion
- severe heart, liver and kidney dysfunction
- combined with thrombotic complications
- people who are pregnant and breastfeeding
- history of other immunosuppressive agents in recent 3 months
- Patients who are not eligible to participate in this trial due to any reason based • • • on the consideration of investigator
Key Trial Info
Start Date :
April 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2022
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03866681
Start Date
April 1 2019
End Date
April 1 2022
Last Update
March 8 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking union medical college hospital
Beijing, China